Effect of Fasting, Endogenous GLP-1 Secretion on B-cell Response to Intravenous Glucose


  • Study type

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 15-006016
    Sponsor Protocol Number: 15-006016

About this study

The purpose of this study is to determine the effect of GLP-1 in priming β-cells for insulin secretion.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • BMI 18 – 35  Kg/M2
  •  Fifteen patients with normal glucose tolerance and fifteen with impaired fasting glucose
  • Participants will be in good health
  • Stable weight
  • Not engaged in regular vigorous exercise
  • No history of diabetes or of prior therapy with antidiabetic medication
  • No history of chronic disease
  • No prior abdominal surgery other than cholecystectomy or appendectomy

Exclusion Criteria:

  • Subjects < 20 years of age or > 65 years of age


Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Open for enrollment

Contact information:

Paula Giesler R.N.